Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, filed on Monday with the SEC to raise up to $50 million in an initial public offering. The New York, NY-based company has two lead candidates, both in Phase 2 clinical trials, for the treatment of leukemia and brain cancer.
Stemline, which was founded in 2003, plans to list on the NASDAQ under the symbol STML. Oppenheimer & Co. and JMP Securities are the joint bookrunners on the deal.
